Faron's Traumakine misses in Phase III for acute respiratory distress syndrome

Faron Pharmaceuticals Oy (LSE:FARN) said Traumakine (FP-1201-lyo) missed the composite primary endpoint in the double-blind, European Phase III INTEREST trial in 300 patients with moderate to severe acute

Read the full 288 word article

User Sign In